RBFOX3 and hepatocellular carcinoma: Higher NeuN immunoreactivity in the PEG-HCC groups indicates neuroprotection after treatment, potentially by the inhibition of neuroinflammation activated by necrotic cell bodies, thus preventing inflammation-activated apoptosis.